title: A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis.
abstract: OBJECTIVE
  This pilot study was designed to evaluate the feasibility of a multicenter, randomized, clinical trial in interstitial cystitis (IC). Secondary objectives were to evaluate the safety and efficacy of oral pentosan polysulfate sodium (PPS), hydroxyzine, and the combination to consider their use in a larger randomized clinical trial.
  
  
  METHODS
  A 2 x 2 factorial study design was used to evaluate PPS and hydroxyzine. Participants met the National Institutes of Health-National Institute for Diabetes and Digestive and Kidney Diseases criteria for IC and reported at least moderate pain and frequency for a minimum of 6 months before study entry. The primary end point was a patient reported global response assessment. Secondary end points included validated symptom indexes and patient reports of pain, urgency and frequency. The target sample size was 136 participants recruited during 10 months.
  
  
  RESULTS
  A total of 121 (89% of goal) participants were randomized over 18 months and 79% provided complete followup data. The response rate for hydroxyzine was 31% for those treated and 20% for those not treated (p = 0.26). A nonsignificant trend was seen in the PPS treatment groups (34%) as compared to no PPS (18%, p = 0.064). There were no treatment differences for any of the secondary end points. Adverse events were mostly minor and similar to those in previous reports.
  
  
  CONCLUSIONS
  The low global response rates for PPS and hydroxyzine suggest that neither provided benefit for the majority of patients with IC. This trial demonstrated the feasibility of conducting a multicenter randomized clinical trial in IC using uniform procedures and outcomes. However, slow recruitment underscored the difficulties of evaluating commonly available IC drugs.
authors.affiliation: New England Medical Center and Tufts University School of Medicine, Boston, MA, USA.
authors.forename: G R
authors.initials: GR
authors.lastname: Sant
authors.forename: K J
authors.initials: KJ
authors.lastname: Propert
authors.forename: P M
authors.initials: PM
authors.lastname: Hanno
authors.forename: D
authors.initials: D
authors.lastname: Burks
authors.forename: D
authors.initials: D
authors.lastname: Culkin
authors.forename: A C
authors.initials: AC
authors.lastname: Diokno
authors.forename: C
authors.initials: C
authors.lastname: Hardy
authors.forename: J R
authors.initials: JR
authors.lastname: Landis
authors.forename: R
authors.initials: R
authors.lastname: Mayer
authors.forename: R
authors.initials: R
authors.lastname: Madigan
authors.forename: E M
authors.initials: EM
authors.lastname: Messing
authors.forename: K
authors.initials: K
authors.lastname: Peters
authors.forename: T C
authors.initials: TC
authors.lastname: Theoharides
authors.forename: J
authors.initials: J
authors.lastname: Warren
authors.forename: A J
authors.initials: AJ
authors.lastname: Wein
authors.forename: W
authors.initials: W
authors.lastname: Steers
authors.forename: J W
authors.initials: JW
authors.lastname: Kusek
authors.forename: L M
authors.initials: LM
authors.lastname: Nyberg
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010426:Pentosan Sulfuric Polyester / Q000627:therapeutic use*; D010865:Pilot Projects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006634:Histamine H1 Antagonists; D006919:Hydroxyzine; D010426:Pentosan Sulfuric Polyester